These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 30509440)

  • 1. Th17 cell responses in spondyloarthritis.
    Gaston JSH; Jadon DR
    Best Pract Res Clin Rheumatol; 2017 Dec; 31(6):777-796. PubMed ID: 30509440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rebamipide prevents peripheral arthritis and intestinal inflammation by reciprocally regulating Th17/Treg cell imbalance in mice with curdlan-induced spondyloarthritis.
    Min HK; Kim JK; Lee SY; Kim EK; Lee SH; Lee J; Kwok SK; Cho ML; Park SH
    J Transl Med; 2016 Jun; 14(1):190. PubMed ID: 27350608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secukinumab: a promising therapeutic option in spondyloarthritis.
    Maldonado-Ficco H; Perez-Alamino R; Maldonado-Cocco JA
    Clin Rheumatol; 2016 Sep; 35(9):2151-61. PubMed ID: 27437696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the interleukin-23/17 axis in axial spondyloarthritis.
    Paine A; Ritchlin CT
    Curr Opin Rheumatol; 2016 Jul; 28(4):359-67. PubMed ID: 27152702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The IL-23/Th 17 pathway in spondyloarthritis: the royal road?
    Wendling D; Guillot X; Prati C
    Joint Bone Spine; 2015 Jan; 82(1):1-4. PubMed ID: 25245641
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical Trials Supporting the Role of the IL-17/IL-23 Axis in Axial Spondyloarthritis.
    Ceribelli A; Motta F; Vecellio M; Isailovic N; Ciccia F; Selmi C
    Front Immunol; 2021; 12():622770. PubMed ID: 34149686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Bench-to-Bedside Story of IL-17 and the Therapeutic Efficacy of its Targeting in Spondyloarthritis.
    Smith JA
    Curr Rheumatol Rep; 2016 Jun; 18(6):33. PubMed ID: 27105640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-23/IL-17 axis in spondyloarthritis-bench to bedside.
    Raychaudhuri SP; Raychaudhuri SK
    Clin Rheumatol; 2016 Jun; 35(6):1437-41. PubMed ID: 27075462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin 27 is a novel cytokine with anti-inflammatory effects against spondyloarthritis through the suppression of Th17 responses.
    Jouhault Q; Cherqaoui B; Jobart-Malfait A; Glatigny S; Lauraine M; Hulot A; Morelle G; Hagege B; Ermoza K; El Marjou A; Izac B; Saintpierre B; Letourneur F; Rémy S; Anegon I; Boissier MC; Chiocchia G; Breban M; Araujo LM
    Front Immunol; 2022; 13():1072420. PubMed ID: 36818477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New treatment options and emerging drugs for axial spondyloarthritis: biological and targeted synthetic agents.
    Toussirot E
    Expert Opin Pharmacother; 2017 Feb; 18(3):275-282. PubMed ID: 28099816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between Th-17 cytokine profile and clinical features in patients with spondyloarthritis.
    Romero-Sanchez C; Jaimes DA; Londoño J; De Avila J; Castellanos JE; Bello JM; Bautista W; Valle-Oñate R
    Clin Exp Rheumatol; 2011; 29(5):828-34. PubMed ID: 22041179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-17-producing CD4+ T cells are increased in early, active axial spondyloarthritis including patients without imaging abnormalities.
    Jansen DT; Hameetman M; van Bergen J; Huizinga TW; van der Heijde D; Toes RE; van Gaalen FA
    Rheumatology (Oxford); 2015 Apr; 54(4):728-35. PubMed ID: 25288779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The interleukin-23/interleukin-17 immune axis as a promising new target in the treatment of spondyloarthritis.
    Yeremenko N; Paramarta JE; Baeten D
    Curr Opin Rheumatol; 2014 Jul; 26(4):361-70. PubMed ID: 24827753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proinflammatory Th17 cells are expanded and induced by dendritic cells in spondylarthritis-prone HLA-B27-transgenic rats.
    Glatigny S; Fert I; Blaton MA; Lories RJ; Araujo LM; Chiocchia G; Breban M
    Arthritis Rheum; 2012 Jan; 64(1):110-20. PubMed ID: 21905004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of HLA-B*27 in spondyloarthritis.
    Colbert RA; Navid F; Gill T
    Best Pract Res Clin Rheumatol; 2017 Dec; 31(6):797-815. PubMed ID: 30509441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-17 and IL-17R: an auspicious therapeutic target for psoriatic disease.
    Mitra A; Raychaudhuri SK; Raychaudhuri SP
    Actas Dermosifiliogr; 2014 Oct; 105 Suppl 1():21-33. PubMed ID: 25398489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ILC3 in Axial Spondyloarthritis: the Gut Angle.
    Mauro D; Macaluso F; Fasano S; Alessandro R; Ciccia F
    Curr Rheumatol Rep; 2019 Jun; 21(7):37. PubMed ID: 31197599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of the IL-23/IL-17 Pathway in the Pathogenesis of Spondyloarthritis.
    Tsukazaki H; Kaito T
    Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32899140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-17 targeted therapies in axial spondyloarthritis.
    Wendling D
    Immunotherapy; 2015; 7(11):1125-8. PubMed ID: 26513376
    [No Abstract]   [Full Text] [Related]  

  • 20. Interleukin-17 Inhibition in Spondyloarthritis Is Associated With Subclinical Gut Microbiome Perturbations and a Distinctive Interleukin-25-Driven Intestinal Inflammation.
    Manasson J; Wallach DS; Guggino G; Stapylton M; Badri MH; Solomon G; Reddy SM; Coras R; Aksenov AA; Jones DR; Girija PV; Neimann AL; Heguy A; Segal LN; Dorrestein PC; Bonneau R; Guma M; Ciccia F; Ubeda C; Clemente JC; Scher JU
    Arthritis Rheumatol; 2020 Apr; 72(4):645-657. PubMed ID: 31729183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.